Compound profile

VIP (Vasoactive Intestinal Peptide)

Endogenous neuropeptide / vasodilator

A 28-amino-acid neuropeptide and vasodilator. Its synthetic form, aviptadil, has been studied clinically with mixed results, while an intranasal version is used off-protocol in the fringe CIRS community.

Reviewed for accuracy · Last reviewed July 8, 2026
ClassEndogenous neuropeptide (VPAC1/VPAC2 agonist)
Synthetic formAviptadil
Community routeIntranasal spray (not validated)
Approval statusNot FDA-approved for these uses

Overview

Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide found throughout the nervous system. In the body it works as a neurotransmitter, a vasodilator, a secretagogue, and an immune regulator, signaling through the VPAC1, VPAC2, and PAC1 receptors. That endogenous biology is well characterized; what is far less settled is whether giving VIP as a drug helps any specific condition.

The synthetic form is called aviptadil, and its clinical record is mixed. A small phase 2 trial of inhaled aviptadil in COVID-19 pneumonia reported faster recovery, but the larger intravenous program (marketed as ZYESAMI) was unconvincing: the FDA declined an Emergency Use Authorization in 2021 and a major NIH-sponsored trial did not meet its primary endpoint. Separately, in the peptide community VIP is used intranasally as part of Ritchie Shoemaker's chronic inflammatory response syndrome (CIRS) protocol. That application is fringe and weakly evidenced: CIRS is not a mainstream-accepted diagnosis, and the intranasal VIP studies behind it are small, open-label, and uncontrolled. Nothing here is FDA-approved for these uses.

Dosing

There is no approved dose. Community intranasal CIRS protocols commonly cite 50 mcg per spray several times daily, but this comes from a single small uncontrolled study and is not validated. Clinical inhaled aviptadil trials used different, protocol-specific dosing.

Read the full VIP (Vasoactive Intestinal Peptide) dosage guide →

Side effects

VIP is a vasodilator, so flushing, low blood pressure, and headache are the expected effects. The safety evidence for the community intranasal use is limited and comes from small, uncontrolled studies.

Read the full VIP (Vasoactive Intestinal Peptide) side effects guide →

Storage

As a peptide, VIP/aviptadil is generally kept refrigerated and protected from light, and reconstituted or compounded preparations are handled per the compounding pharmacy's instructions. See the full storage & safety guide for general handling and disposal basics.

FAQ

Is VIP the same thing as aviptadil?Aviptadil is the synthetic pharmaceutical form of the natural peptide VIP. Community intranasal products and the clinical inhaled/IV products both use aviptadil.
Is intranasal VIP proven to treat CIRS?No. The CIRS framework is not a mainstream-accepted diagnosis, and the intranasal VIP studies behind it are small, open-label, and uncontrolled. Treat any benefit claims as weakly evidenced.
Did aviptadil work for COVID-19?The picture is mixed. One small inhaled phase 2 trial reported faster recovery, but the larger intravenous program did not gain FDA authorization and a major trial missed its primary endpoint.

References

  1. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functionsAmino Acids · 2013 · PMID 22139413 · DOI 10.1007/s00726-011-1184-8
  2. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19Medical Principles and Practice · 2025 · PMID 39870064 · DOI 10.1159/000543773
  3. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildingsHealth (Scientific Research Publishing) · 2013 · DOI 10.4236/health.2013.53053
Tracking an intranasal protocol? PepHub can log doses, though remember this use is not validated.Coming soon

This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.